By BullScreen Editorial Team 
Alkem Laboratories has nearly doubled its planned investment in its Ujjain manufacturing facility, raising the cap from Rs 533 crore to Rs 1,036 crore. The company’s Board of Directors approved the decision on Wednesday, signaling a significant expansion of its greenfield formulations project.
The Ujjain plant, initially announced on March 18, 2026, will be built on approximately 30 acres of land in Phase-2 of the DMIC Vikram Udyogpuri Industrial Area. The expanded investment indicates a larger facility than initially planned. Funds will be released in phases, with construction and capacity building progressing in stages. The company has not provided a specific timeline for project completion.
Alkem Laboratories’ stock attracted investor attention following the announcement, trading at Rs 5,276.50 on the BSE and NSE, up 0.61 percent from its previous close. Despite the recent gain, the stock has recorded a negative return of 7.84 percent over the past year.
The move highlights Madhya Pradesh’s growing importance as a pharmaceutical manufacturing hub. Alkem’s increased commitment reflects confidence in the region and underscores its strategy to scale production capacity. The new facility is expected to strengthen the company’s core formulations business, which serves both domestic and international markets.
By investing over Rs 1,000 crore, Alkem positions itself to meet rising demand for medicines and enhance output capabilities. The phased approach to construction allows the company to manage expenditure while gradually ramping up operations. Industry analysts see this as a strategic step toward long-term growth in India’s pharmaceutical sector.